Consultation outcome

Proposal to make Dovonex Psoriasis Ointment available from Pharmacies

This consultation has concluded

Download the full outcome

Detail of outcome

The Medicines and Healthcare products Regulatory Agency (MHRA) has agreed to reclassify Dovonex Psoriasis 50 microgram/g Ointment from a prescription only medicine (POM) to a Pharmacy (P) medicine in the UK for treatment of mild to moderate plaque psoriasis which has been previously diagnosed by a doctor in adults aged 18 years of age and over.

See public assessment report for more information.

Feedback received

Dispensing Doctor’s Association (DDA) response

British Association of Dermatologists (BAD) response

Psoriasis and Psoriatic Arthritis Association (PAPAA) response

National Pharmacy Association (NPA) response

Proprietary Association of Great Britain (PAGB) response

Royal Pharmaceutical Society (RPS) response

Dermatology Pharmacist response

Patient response

Patient 3 response

Patient 2 response

Detail of feedback received

A total of 14 responses were received, of which 12 were in favour and 2 were not in favour. 4 of the responses were confidential and 1 partially confidential.

See all the responses to this consultation that are not confidential

Original consultation

Summary

We are considering making Dovonex Psoriasis 50 microgram/g Ointment available to buy from pharmacies. We always want to involve the public and healthcare professionals in decisions that affect them. We want to know what you think about this change.

This consultation ran from
to

Consultation description

We want to know what you think

  • Dovonex Psoriasis 50 microgram/g Ointment is used to treat mild to moderate plaque psoriasis which has been previously diagnosed by a doctor in adults aged 18 years and over.
  • Calcipotriol is only at the moment available on prescription (known as Dovonex Ointment).
  • We propose to make it available in pharmacies without prescription.
  • The Commission on Human Medicines has advised that this product can be available as a pharmacy medicine.
  • We want to know what you think about this change.

Please tell us your views using the attached document.

This consultation closes at 5pm on 20 April 2017

Documents

Published 30 March 2017
Last updated 17 August 2017 + show all updates
  1. Reclassification has been approved by MHRA.
  2. First published.